Cannabis
The “Pot” Thickens – IRS Releases Marijuana Industry Resources
The IRS has released a new webpage dedicated to the marijuana industry to help growers, processors, researchers and retailers understand and comply with their U.S. federal income tax responsibilities. The IRS Marijuana Industry webpage covers numerous topics that may be relevant for businesses directly engaged in, or related to, the cultivation, processing and sale of marijuana, including, without limitation, common U.S. federal income tax filing obligations, options for satisfying U.S. federal income tax liabilities, and penalties which will be assessed if such payment obligations are not satisfied on a timely basis. Perhaps of most significance, the IRS Marijuana Industry webpage also contains a series of FAQs including information on a number of common questions, including the potential application of Section 280E of the U.S. Internal Revenue Code to taxpayers in the marijuana industry. The IRS webpage dedicated to the Marijuana Industry can be accessed at: https://www.irs.gov/businesses/small-businesses-self-employed/marijuana-industry
September 23, 2020
by Kendall R. Fisher and John D. Hollinrake, Jr.
Cannabis
Delaware Takes Action Against Formation of Cannabis Companies
As reported earlier today on our Cannabis blog, the Delaware Secretary of State’s office is now threatening to prevent the formation of companies that it identifies as having the purpose of being involved in the cannabis industry. For more information, see dorseycann.com/delaware-takes-action-against-formation-of-cannabis-companies/.
October 15, 2019
by Christopher L. Doerksen
Cannabis
Canada-U.S. Trade in Marijuana-Related Products is Fraught with Peril
Now that Canada allows using and producing marijuana and marijuana-related products, and bordering U.S. states like Washington, Maine, and Michigan have similarly relaxed marijuana-related laws, it seems natural that industries on both sides of the border will look for cross-border business opportunities. But cross-border transactions between the Canadian and U.S. marijuana industries face a potentially insurmountable obstacle: items primarily intended for the marijuana industry are considered prohibited drug paraphernalia and are illegal to import into or export from the United States. We refer to this statute as the Paraphernalia Statute. The Paraphernalia Statute prohibits paraphernalia from being imported into, exported from, or transported across U.S. state lines. The statute also prohibits the use of the mail to transport drug paraphernalia. Even merely offering paraphernalia for sale in the United States is a federal criminal offense. U.S. Customs and Border Protection (“CBP”) takes custody of each import prior to release the goods to the importer or consignee, giving CBP a powerful means to enforce the Paraphernalia Statute. CBP has the authority to seize and forfeit any merchandise that is considered to be contraband under federal law. Likewise, CBP can halt an outward bound shipment of an item prohibited for exportation from the United States and seize and forfeit drug paraphernalia. Besides the loss of the merchandise itself, importers and exporters also could become subject to criminal penalties. Most people would not be surprised to learn that CBP may seize items intended to inhale or ingest drugs, but the breadth of what is considered “paraphernalia” under U.S. law may not be widely understood, and goes far beyond items merely designed for marijuana consumption. The Paraphernalia Statute defines paraphernalia as equipment, products, or materials primarily intended or designed for use in manufacturing, compounding, converting, concealing, producing, processing, preparing, injecting, ingesting, inhaling, or otherwise introducing into the human body a controlled substance. The Supreme Court has interpreted the phrase designed for to mean that items principally used with illegal drugs by virtue of features designed by the manufacturer are prohibited items under the Paraphernalia Statute. In addition, the phrase primarily intended, according to the Supreme Court, focuses not only on the objective features of the item, but also what the “likely use” of the item is by users. By way of example, production and harvesting equipment likely would be considered drug paraphernalia if it had particular attributes unique to the marijuana plant. CBP has found, for example, that cannabis grinders are prohibited by the Paraphernalia Statute from being imported because they were marketed for marijuana grinding, and the importer did not submit evidence of non-drug uses for the grinders. The statute could potentially cover health- or production-related equipment primarily used with drugs or drug plants. Companies should not take comfort in the legally ambiguous test about what constitutes prohibited paraphernalia because the penalties for being wrong are severe, and CBP and third parties can raise the issue. CBP can independently assess whether an import or export is prohibited under the Paraphernalia Statute, even if no party raises the issue. In addition, carriers and importers can ask CBP to interpret the Paraphernalia Statute to determine whether the import ban applies. This happened most recently in April 2017 when a carrier received confirmation from CBP that items shipped by the not-so-cleverly-named Stashlogix were in fact prohibited from import. The penalties for violating the Paraphernalia Statute, moreover, are severe and include potential prison time, CBP seizures, and hefty fines as a result of an offense. CBP has rejected arguments that statutory exceptions permit state laws to provide a safe harbor for importing or exporting drug paraphernalia. The Paraphernalia Statute exempts persons “authorized by…state…law to manufacture, possess or distribute such items.” An importer argued to CBP that, even assuming its marijuana accessories are paraphernalia, the Paraphernalia Statute authorized its activities because they were legal under Colorado law. CBP rejected the argument holding, among other things, that the statute could not be read as proposed by the importer and, in any event, the U.S. Constitution prohibited the result, because, under the “Supremacy Clause,” federal legislation supersedes and displaces inconsistent state law. Until a federal court overrules CBP on this interpretation of the law, importers and exporters must assume that state law is not a viable defense under the Paraphernalia Statute. CBP’s interpretation also raises the question: what is the status of state-licensed or authorized distributors of marijuana-related equipment under the Paraphernalia Statute? As with federal law generally, it remains to be seen how vigorously enforcement authorities will penalize violators of the Paraphernalia Statute. CBP’s actions to date, however, suggest that it will take action against offending imports or exports. For example, CBP has indicated that it could cite a non-citizen’s investment in cannabis business as grounds to bar admission into the United States under immigration law. Entities that are focused on the marijuana industry should take action to prevent cross-border transactions unless they are certain the items involved are not considered paraphernalia. Finally, application of the Paraphernalia Statute to trade between Canada and the United States could become a flashpoint in the larger debate about the extent to which federal prohibitions related to marijuana should be enforced. At the least, companies should avoid testing the boundaries of what are prohibited items under the Paraphernalia Statute and CBP’s willingness to enforce the statute.
December 20, 2018
by T. Augustine Lo and Dave Townsend
Cannabis
Canadians Involved in Cannabis Industry Should be Careful Crossing the U.S. Border
With the legalization of marijuana going into effect in Canada tomorrow, October 17, we encourage our Canadian contacts to be careful when crossing the U.S. Border. For more information, see the recent article authored by Dorsey’s Immigration Practice Group posted on our Cannabis Blog here: dorseycann.com/at-the-intersection-of-cannabis-and-u-s-immigration-law-issues-that-canadians-and-other-non-citizens-should-be-aware-of/.
October 16, 2018
by Christopher L. Doerksen
Cannabis
Canadian Cannabis Companies Begin to Trade on National Stock Exchanges in the United States
With the listing on May 24th of Canopy Growth Corporation (Canopy) on the New York Stock Exchange (NYSE), both NASDAQ and the NYSE have permitted Canadian cannabis companies to trade on their respective exchanges. Canopy, the first Canadian cannabis company to list on the NYSE, follows Cronos Group Inc. (Cronos), which was the first Canadian cannabis company to list on a national stock exchange in the United States when it listed on NASDAQ in February. While neither exchange has formally adopted a policy on the listing of cannabis companies, informally they are willing, on a case-by-case basis, to accept a company with cannabis operations, so long as the company complies with all relevant laws in the jurisdictions where it operates. This is similar to the policies adopted by the Toronto Stock Exchange and TSX Venture Exchange, which prohibit the listing of cannabis companies with U.S. operations. In order to list in the United States, each of Canopy and Cronos filed listing applications with the respective exchange and registered their class of common shares with the United States Securities and Exchange Commission (SEC). A Canadian company that has been a reporting issuer in Canada for at least 12 months and has a public float of at least US$75 million is eligible to take advantage of the Multijurisdictional Disclosure System (MJDS) in order to register with the SEC. The MJDS permits such Canadian companies to file a Form 40-F registration statement, which is essentially a wrap around the company’s Canadian disclosure documents and is not subject to the typical burdensome SEC comment process. This generally permits for a quicker and less costly process for Canadian companies wishing to enter the U.S. markets. For more information on listing in the United States, contact your relationship attorney at Dorsey. For more information about Dorsey's cannabis industry practice, visit www.dorsey.com/services/cannabis.
June 7, 2018
by James Guttman
Cannabis
California Opens Applications for Temporary Cannabis Licenses
California is now accepting applications for temporary cannabis licenses. For more information, see www.dorsey.com/newsresources/publications/client-alerts/2017/12/ca-opens-applications-for-temporary-cannabis.
December 12, 2017
by Kenneth G. Sam
Cannabis
California Adopts Emergency Cannabis Regulations for Licensing Beginning on January 1, 2018
On November 16, 2017, California published the long awaited rules and regulations to implement voter approved Proposition 64, the Adult Use of Cannabis Act of 2016, which legalized adult use of cannabis in the State of California. The California Legislature passed and the Governor signed into law the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA), which creates the general framework for the regulation of both commercial medicinal and adult-use (recreational) cannabis. The State agencies that regulate cannabis, the Bureau of Cannabis Control (distribution, testing, retail and microbusiness), Department of Food and Agriculture (cultivation) and Department of Public Health (manufacturing), established new regulations under an “emergency” rule-making process for commercial medicinal and adult-use (recreational) cannabis industries. The “emergency” regulations will be followed by a formal rule-making process beginning next year. California’s new cannabis regulations will be of interest to the growing number of Canadian companies and investors involved in the cannabis industry. The regulations include: Temporary Permits – In December 2017, California will begin accepting on-line applications for temporary business permits. Priority application review will be provided for annual licenses applicants that were in operation under the Compassionate Use Act prior to September 1, 2016. Temporary permits will be good for four months (120 days) for cannabis businesses, which may be extended for two 90-day extensions (only if the temporary licensee has applied for an annual license). There is no fee for temporary permits. Cannabis businesses will need local approval for conducting commercial cannabis activities, which must be demonstrated to receive a temporary permit. Beginning January 1, 2018, an email notification will be issued from the State confirming that a temporary permit has been approved. Transitional Rules – Licensed cannabis companies will have a six-month grace period (until July 1, 2018) to sell products in their inventory (with specified labeling) that do not comply with regulation (testing and labeling) guidelines and may work with other licensed businesses without worrying about whether their permits are for medical and recreational activities. During the transitional period, licensees will not be required to use the State’s track-and-trace system but will need to complete manifests and other paperwork to keep track of cannabis products. Two Types of Licenses – There will be two types of licenses: A-License (adult use) and M-License (medical cannabis). It is unclear whether an A-license can be used for a medical dispensary or a business would require separate A and M licenses. Testing labs may test cannabis goods for both types of licenses. License Fees/Activities – Annual cannabis license fees are based on a sliding scale ranging from $800 to $120,000 based on activity and revenues. Activities include retail operations, cannabis events, distribution, cultivation, manufacturing and products, laboratory testing and microbusiness (multiple commercial cannabis activities are permitted under one license). Retail Operations: Adult-use cannabis sales are limited to adults 21 years and over. Stores cannot be located within 600 feet of schools (K-12 school, day care center, or youth center), must close by 10:00 p.m., and must have 24-hour surveillance. There are limitations on purchases (adult-use customers may purchase up to one ounce and medical patients up to eight ounces or more with physician’s note). Only medical cannabis patients or their caregivers will be permitted to receive free cannabis products or samples. Products must be packaged, tested and labeled. Advertising is limited. Distribution: Only a licensed distributor may transport cannabis. Cannabis Manufacturing and Products: The California Department of Public Health (CDPH) is responsible for regulation of manufacturing of cannabis. Manufacturing licenses (A-License and M-Licenses) fall under four license types: Type 7: Extraction using volatile solvents; Type 6: Extraction using non-volatile solvents or mechanical method; Type N: Infusions; and Type P: Packaging and labeling only. All cannabis products must contain a State-mandated warning label and the CDPH-issued universal symbol and must be tested. Edible products may not be in shapes that may appeal to children – no human beings, animals, insects, or fruit shapes. There are limits on THC content. Licensees must have written procedures for inventory control, quality control, transportation, security and cannabis waste disposal. Good manufacturing practices must be followed. Cannabis Cultivation: The California Department of Food and Agriculture regulates the cultivation of commercial cannabis. Cultivation of cannabis is divided into three categories: Cultivators (commercial cultivators); Nurseries (cloning and seed propagation) and Processors (trimming, drying, curing, grading, or packaging). Testing Laboratories: All cannabis goods must meet certain health and safety standards before they can be sold to consumers. To ensure that cannabis goods meet those standards, a representative sample of the cannabis goods must be tested by a licensed testing laboratory. The regulations provide the minimum laboratory-operation requirements, which would include requirements such as sampling procedures, personnel qualifications, standard operating procedures, and recordkeeping requirements. Ownership – License “owners” must submit fingerprints (via the Department of Justice’s Live Scan service) and background information including any past criminal convictions. An “owner” includes the CEO, a board member, a person holding 20% or more ownership interest and any person participating in the direction, control, or management of the person applying for a license. Individuals that are employed by the State of California or district attorney’s offices and law enforcement agencies are prohibited from holding a license when the duties of their employment have to do with enforcement of cannabis regulations. Financial Interests – The license application must disclose the holders of “financial interests” (any investment, loan or any other equity interest), including the holder’s name, birth date and a government issued ID. Holders of financial interests that are not required to be listed: (a) a bank or financial institution whose interest constitutes a loan; (b) individuals whose only financial interest in the commercial cannabis business is through an interest in a diversified mutual fund, blind trust, or similar instrument; (c) individuals whose only financial interest is a security interest, lien, or encumbrance on property that will be used by the commercial cannabis business; and (d) individuals who hold a share of stock that is less than 5 percent of the total shares in a publicly traded company. Labor and Employment – License applicants with more than 20 employees must attest that they have entered into a labor peace agreement (in which the employer agrees not to resist organizing attempts by its workers) and provide a copy to the Bureau of Cannabis Control. If no such agreement exists, the license applicant will have to provide a notarized statement indicating that the company will enter into a labor peace agreement. Surety Bond – License applicants must obtain a surety bond of $5,000, payable to the State as obligee, to ensure payment of cost incurred for the destruction of cannabis product necessitated by violation of the MAUCRSA or regulations. For a more complete summary of the regulations visit: www.dorsey.com/newsresources/publications/client-alerts/2017/11/ca-emergency-cannabis-regulations Federal Law Warning: The United States federal government regulates drugs through the Controlled Substances Act (21 U.S.C. § 811), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug. A Schedule I controlled substance is defined as a substance that has no currently accepted medical use in the United States, a lack of safety for use under medical supervision and a high potential for abuse. The Department of Justice defines Schedule 1 controlled substances as “the most dangerous drugs of all the drug schedules with potentially severe psychological or physical dependence.” The United States Federal Drug Administration has not approved the sale of marijuana for any medical application. State laws regulating cannabis are in direct conflict with the federal Controlled Substances Act, which makes cannabis use and possession federally illegal.
November 28, 2017
by Jason Brenkert and Kenneth G. Sam
